Financing

A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted…

This report provides an analysis of donor government funding to address family planning in low- and middle-income countries in 2022, which totaled US$1.35 billion and was a decline of 9% (US$129 million) compared to the 2021 amount (US$1.48 billion). While the decline was due to decreases in funding by most donor governments, a significant share can be attributed to exchange rate fluctuations resulting from the rise in value of the U.S. dollar against most currencies during 2022.

A new KFF analysis finds donor government funding for family planning efforts in low- and middle-income countries totaled US$1.35 billion in 2022, a decline of 9% (US$129 million) compared to 2021 ($1.48 billion). This figure marks the lowest level of funding since 2016 ($1.31 billion). While some of the decline…

This data note estimates that the value of tax exemption for nonprofit hospitals was $28 billion in 2020. This amount exceeds estimated charity care costs among nonprofit hospitals in 2020 ($16 billion), though charity care represents only a portion of the community benefits reported by nonprofit hospitals.

This interactive provides the facts on Medicare spending. Medicare, which serves 65 million people and accounts for 12 percent of the federal budget and 20 percent of national health spending, is at the heart of discussions about health expenditures and affordability. Explore data on enrollment growth, Medicare spending trends overall and per person, growth in Medicare spending relative to private insurance, spending on benefits and Medicare Advantage, Part A trust fund solvency challenges, and growth in out-of-pocket spending.

This data note provides details on the FY25 request for domestic HIV programs and comparisons to the FY23 enacted level, where possible.

This page provides access to the reports stemming from the 50-state Medicaid budget surveys published annually since 2000 by the Kaiser Family Foundation (KFF). It tracks trends in Medicaid spending and enrollment, as well as Medicaid policy actions around eligibility and enrollment, provider rates, provider taxes/fees, premiums and cost-sharing, benefits and pharmacy, long-term care and delivery system and payment reform.

Section 1115 Medicaid demonstration waivers offer states an avenue to test new approaches in Medicaid that differ from what is required by federal statute, so long as the approach is likely to “promote the objectives of the Medicaid program.” As with broader Medicaid policy, the future landscape of Section 1115 waivers depends on the outcome of the November 2024 presidential election as a new administration could focus on different priorities, rescind existing guidance, or withdraw already-approved waivers. This waiver watch summarizes five key areas of difference in 1115 waiver policy and waiver approvals under the Trump and Biden-Harris administrations.

This brief analyzes Medicaid enrollment and spending trends for FY 2024 and FY 2025, based on data provided by state Medicaid directors as part of the 24th annual survey of Medicaid directors.

This fact sheet shares information about the World Health Organization (WHO) and U.S. government funding and engagement with WHO.